A Trial to Assess the Safety and Tolerability of Repeated Doses of Intravitreal Administration of Two VEGF Trap Formulations in Subjects With Neovascular Age Related Macular Degeneration
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 主要终点
- The primary endpoint of the study will be safety and tolerability of the study treatment at Week 12 as assessed by ophthalmic examination and reporting of AEs.
研究概览
简要总结
To assess the safety and tolerability of repeated intravitreal (ITV) administration of VEGF Trap.
详细描述
A double-masked study in which approximately 12 subjects will receive ITV injections of VEGF Trap every 4 weeks for a total of 3 doses. Once the subjects have received the 3 doses allowed in this study, they will be evaluated every 4 weeks for continued dosing of VEGF Trap for an additional 9 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subfoveal CNV secondary to AMD.
- •Central retinal (including lesion) thickness ≥ 250 µm as measured by OCT.
- •ETDRS best-corrected visual acuity (BCVA) of 20/40 to 20/400 (73 to 20 letters)
排除标准
- •No prior treatment with the following in the study eye:
- •Subfoveal thermal laser therapy;
- •Submacular surgery or other surgical intervention for the treatment of AMD;
- •Extrafoveal laser coagulation treatment within 12 weeks prior to Day 1 (Visit 2);
- •PDT or ITV administration of triamcinolone acetonide or any other steroid within 12 weeks prior to Day 1 (Visit 2);
- •Pegaptanib sodium within 8 weeks of Day 1 (Visit 2);
- •Juxtascleral steroids or anecortave acetate within 180 Days (6 months) prior to Day 1 (visit 2);
- •Prior systemic or intravitreal treatment with VEGF Trap or bevacizumab;
- •Any investigational agent for the treatment of eye disease within 12 weeks of Day 1 (Visit 2)
- •History of any vitreous hemorrhage within 4 weeks prior to baseline injection visit.
- •Aphakia or pseudophakia with the absence of a posterior capsule (unless it occurred as a result of a yttrium aluminum garnet [YAG] capsulotomy).
- •Significant subfoveal atrophy or scarring.
- •Any condition or laboratory abnormality that, in the opinion of the Investigator, would interfere with the assessment of disease status/progression or jeopardize the subject's appropriate participation in this study
研究组 & 干预措施
ITV-1
VEGF Trap formulation 1
干预措施: VEGF Trap (Biological)
ITV-2
VEGF Trap formulation 2
干预措施: VEGF Trap (Biological)
ITV-2 OL
VEGF Trap formulation 2 open label, higher concentration
干预措施: VEGF Trap (Biological)
结局指标
主要结局
The primary endpoint of the study will be safety and tolerability of the study treatment at Week 12 as assessed by ophthalmic examination and reporting of AEs.
时间窗: 12 weeks
次要结局
未报告次要终点